An Approach to Explore for a Sweet-spot in Randomized Trials.

[1]  Sally Morton,et al.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration , 2019, Annals of Internal Medicine.

[2]  Sally Morton,et al.  The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement , 2019, Annals of Internal Medicine.

[3]  F. Song,et al.  Justification and reporting of subgroup analyses were lacking or inadequate in randomized controlled trials. , 2019, Journal of clinical epidemiology.

[4]  Anthony C H Tung,et al.  Noninferiority drug trials fail to report adequate methodological detail: an assessment of noninferiority trials from 2010 to 2015. , 2019, Journal of clinical epidemiology.

[5]  Sören R. Künzel,et al.  Metalearners for estimating heterogeneous treatment effects using machine learning , 2017, Proceedings of the National Academy of Sciences.

[6]  Krishna S. Vyas,et al.  Aesthetic Goldilocks mastectomy and breast reconstruction: promoting its use in the ideal candidate. , 2018, Gland surgery.

[7]  Catherine R. Lesko,et al.  Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. , 2018, Journal of clinical epidemiology.

[8]  Maarten van Smeden,et al.  Measurement error is often neglected in medical literature: a systematic review. , 2018, Journal of clinical epidemiology.

[9]  R. Tibshirani,et al.  Methods for analyzing matched designs with double controls: excess risk is easily estimated and misinterpreted when evaluating traffic deaths. , 2018, Journal of clinical epidemiology.

[10]  Stefan Wager,et al.  Estimation and Inference of Heterogeneous Treatment Effects using Random Forests , 2015, Journal of the American Statistical Association.

[11]  L. Morrison,et al.  Prehospital cooling to improve successful targeted temperature management after cardiac arrest: A randomized controlled trial. , 2017, Resuscitation.

[12]  D. Pinto,et al.  Risk Prediction in AMI Shock: Goldilocks and the Search for "Just Right". , 2017, Journal of the American College of Cardiology.

[13]  Paul Jhun,et al.  The Neonatal Airway and the Goldilocks Phenomenon. , 2017, Annals of emergency medicine.

[14]  Donald A Redelmeier,et al.  A simple method for analyzing matched designs with double controls: McNemar's test can be extended. , 2017, Journal of clinical epidemiology.

[15]  Issa J Dahabreh,et al.  Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. , 2016, International journal of epidemiology.

[16]  Deepak L. Bhatt,et al.  Adaptive Designs for Clinical Trials. , 2016, The New England journal of medicine.

[17]  Susan Athey,et al.  Recursive partitioning for heterogeneous causal effects , 2015, Proceedings of the National Academy of Sciences.

[18]  K. Kroenke,et al.  Pragmatic characteristics of patient-reported outcome measures are important for use in clinical practice. , 2015, Journal of clinical epidemiology.

[19]  Jeremy B Sussman,et al.  Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program , 2015, BMJ : British Medical Journal.

[20]  A. Hoes,et al.  Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. , 2014, Journal of clinical epidemiology.

[21]  M. Drake.  Vitamin D and the goldilocks principle: too little, too much, or just right? , 2014, The Journal of clinical endocrinology and metabolism.

[22]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[23]  Elizabeth A Stuart,et al.  Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[24]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[25]  James A Hanley,et al.  Random measurement error and regression dilution bias , 2010, BMJ : British Medical Journal.

[26]  Andrea Manca,et al.  A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. , 2010, Journal of clinical epidemiology.

[27]  W. Ray,et al.  Use of disease risk scores in pharmacoepidemiologic studies , 2009, Statistical methods in medical research.

[28]  B. Hansen.  The prognostic analogue of the propensity score , 2008 .

[29]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[30]  C. Naylor,et al.  Interpretation of subgroup results in clinical trial publications: insights from a survey of medical specialists in Ontario, Canada. , 2006, American heart journal.

[31]  A. Kadish.  Prophylactic defibrillator implantation--toward an evidence-based approach. , 2005, The New England journal of medicine.

[32]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[33]  J. Penston,et al.  Large-scale randomised trials--a misguided approach to clinical research. , 2005, Medical hypotheses.

[34]  Sara T Brookes,et al.  Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.

[35]  Jan Vos,et al.  A flexible sigmoid function of determinate growth. , 2003, Annals of botany.

[36]  S. Pocock,et al.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.

[37]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[38]  R Peto,et al.  Trials: the next 50 years , 1998, BMJ.

[39]  D A Redelmeier,et al.  Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. , 1997, American journal of respiratory and critical care medicine.

[40]  S. Senn.  Testing for baseline balance in clinical trials. , 1994, Statistics in medicine.

[41]  R. Chappell,et al.  The Goldilocks dilemma in survey design and its solution. , 1993, Journal of clinical epidemiology.

[42]  D. G. Altman,et al.  Randomisation and baseline comparisons in clinical trials , 1990, The Lancet.

[43]  S J Senn,et al.  Covariate imbalance and random allocation in clinical trials. , 1989, Statistics in medicine.

[44]  R. Tibshirani,et al.  A family of proportional- and additive-hazards models for survival data. , 1983, Biometrics.

[45]  R Tibshirani,et al.  A plain man's guide to the proportional hazards model. , 1982, Clinical and investigative medicine. Medecine clinique et experimentale.

[46]  D. Rubin.  Matched Sampling for Causal Effects: Matching to Remove Bias in Observational Studies , 1973 .